Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroquinone 4% versus hydroquinone 4% plus intradermal autologous platelet-rich plasma for melasma (split-face controlled trial)
TCTR20210925002Phase 4Recruiting
- Sponsor
- St John's Institute of Dermatology
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroquinone in melasma (2 arms), sponsored by St John's Institute of Dermatology. Started Sep 2021; status: recruiting.
02
Drugs
hydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on TCTR20210925002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210925002.